Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/1/2025

Rifaximin Dosage and Efficacy for Diarrhea

Dosing by Indication

  • The American Gastroenterological Association (AGA) endorses a regimen of 550 mg three times daily for 14 days for Irritable Bowel Syndrome with Diarrhea (IBS-D), based on moderate-quality evidence from phase 3 trials 1, 2
  • Patients with IBS-D who respond initially but experience symptom recurrence can be retreated up to 2 times with the same dosage regimen of 550 mg three times daily for 14 days 1, 2, 3

Important Clinical Considerations

  • For non-invasive pathogens, rifaximin is highly effective, but for invasive pathogens, such as Shigella, Campylobacter, and Salmonella, azithromycin is preferred over rifaximin 5
  • The AGA recommends against exceeding 2 retreatment courses for IBS-D, as safety data beyond this are limited 1, 2

Safety Profile

  • Rifaximin has a low risk of Clostridium difficile infection compared to systemically absorbed antibiotics 6